MSD announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet
5 March 2014 | By Merck
MSD announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237)...